The long-term follow-up of the Veteran Affairs Diabetes Trial is important for researchers and clinicians. For the former, this study supports the conclusion that dysglycaemia causes cardiovascular outcomes; for the latter, it shows that in high-risk individuals, the benefits of lowering glucose are modest and take a long time to emerge.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Cardiovascular Diabetology Open Access 27 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hayward, R. A. et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372, 2197–2206 (2015).
Gerstein, H. C. & Werstuck, G. H. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes Endocrinol. 1, 71–78 (2013).
Orchard, T. J. et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 313, 45–53 (2015).
Bradford-Hill, A. The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295–300 (1965).
Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).
Li, G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474–480 (2014).
Ross, S. et al. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur. Heart J. 36, 1454–1462 (2015).
Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).
Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologica 52, 2288–2298 (2009).
Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The Department of Medicine and the Population Health Research Institute at McMaster University and Hamilton Health Sciences have received peer-reviewed and industry-funded grants for studying the effect of glucose lowering and glucose lowering drugs on cardiovascular outcomes from Eli Lilly and Sanofi.
Rights and permissions
About this article
Cite this article
Gerstein, H. Dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol 11, 508–510 (2015). https://doi.org/10.1038/nrendo.2015.118
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.118
This article is cited by
-
Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study
Diabetology International (2023)
-
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Cardiovascular Diabetology (2021)
-
Impact of Bariatric Surgery in Reducing Macrovascular Complications in Severely Obese T2DM Patients
Obesity Surgery (2021)
-
Type 1 diabetes mellitus
Nature Reviews Disease Primers (2017)
